Observations From Long Term Responders in the Gefitinib (Iressa) Expanded Access Program (EAP)

October 11, 2011 updated by: AstraZeneca
The purpose of the study is to determine patient characteristics from patients that have used Iressa for a period of minimal 3 years.

Study Overview

Status

Completed

Study Type

Observational

Enrollment (Actual)

10

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Amsterdam, Netherlands
        • Research Site
      • Apeldoorn, Netherlands
        • Research Site
      • Den Haag, Netherlands
        • Research Site
      • Groningen, Netherlands
        • Research Site
      • Helmond, Netherlands
        • Research Site
      • Hengelo, Netherlands
        • Research Site
      • Hoofddorp, Netherlands
        • Research Site
      • Leiden, Netherlands
        • Research Site
      • Veldhoven, Netherlands
        • Research Site
      • Venlo, Netherlands
        • Research Site
      • Zutphen, Netherlands
        • Research Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Patients from the gefitinib Expanded Access Programme in the Netherlands.

Description

Inclusion Criteria:

  • Participation in the gefitinib Expanded Access Program
  • Patient still uses gefitinib in September 2009

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
The following characteristics of the 'long-term responders' from the EAP; gender, ethnicity, smoking history (pack years), EGFR-TK mutation and histology of NSCLC.
Time Frame: Characteristics will be recorded once, retrospectively
Characteristics will be recorded once, retrospectively

Secondary Outcome Measures

Outcome Measure
Time Frame
To assess the long-term safety in subjects treated with gefitinib by collecting information on: All adverse events that have lead to an interruption/reduction of gefitinib or another intervention
Time Frame: Once, retrospectively for the period the patient has used gefitinib (minimal 3 years)
Once, retrospectively for the period the patient has used gefitinib (minimal 3 years)
long-term safety in subjects; what real life data measures are being taken by lung physicians to counter side effects caused by long term gefitinib treatment; the number, reason, effect and description of interventions that have been taken
Time Frame: Once, retrospectively for the period the patient has used gefitinib (minimal 3 years)
Once, retrospectively for the period the patient has used gefitinib (minimal 3 years)
long-term safety: Number, reason and effect of interruptions during gefitinib use to determine side effects typical for the long-term treatment with gefitinib
Time Frame: Once, retrospectively for the period the patient has used gefitinib (minimal 3 years)
Once, retrospectively for the period the patient has used gefitinib (minimal 3 years)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

March 1, 2010

Primary Completion (Actual)

December 1, 2010

Study Completion (Actual)

December 1, 2010

Study Registration Dates

First Submitted

April 5, 2010

First Submitted That Met QC Criteria

April 13, 2010

First Posted (Estimate)

April 14, 2010

Study Record Updates

Last Update Posted (Estimate)

October 12, 2011

Last Update Submitted That Met QC Criteria

October 11, 2011

Last Verified

October 1, 2011

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe